PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Detalles Bibliográficos
Autores principales: Mohammed, Turab, Shahzad, Moazzam, Peres, Lauren, Khadka, Sushmita, Colinleitzinger, Christelle, Babu, Abida, Doyle, William, Puglianini, Omar Castaneda, Oswald, Laura, De Avila, Gabe, Grajales-Cruz, Ariel, Blue, Brandon, Ochoa-Bayona, Jose, Smith, Eric, Corallo, Salvatore, Khimani4, Farhad, Faramand, Rawan, Elmariah, Hany, Lazaryan, Aleksandr, Jain, Michael, Liu, Hien, Nishihori, Taiga, Shain, Ken, Baz, Rachid, Alsina, Melissa, Locke, Frederick, Freeman, Ciara, Hansen, Doris
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Publication Only
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429647/
http://dx.doi.org/10.1097/01.HS9.0000975160.46377.e2
_version_ 1785090766330134528
author Mohammed, Turab
Shahzad, Moazzam
Peres, Lauren
Khadka, Sushmita
Colinleitzinger, Christelle
Babu, Abida
Doyle, William
Puglianini, Omar Castaneda
Oswald, Laura
De Avila, Gabe
Grajales-Cruz, Ariel
Blue, Brandon
Ochoa-Bayona, Jose
Smith, Eric
Corallo, Salvatore
Khimani4, Farhad
Faramand, Rawan
Elmariah, Hany
Lazaryan, Aleksandr
Jain, Michael
Liu, Hien
Nishihori, Taiga
Shain, Ken
Baz, Rachid
Alsina, Melissa
Locke, Frederick
Freeman, Ciara
Hansen, Doris
author_facet Mohammed, Turab
Shahzad, Moazzam
Peres, Lauren
Khadka, Sushmita
Colinleitzinger, Christelle
Babu, Abida
Doyle, William
Puglianini, Omar Castaneda
Oswald, Laura
De Avila, Gabe
Grajales-Cruz, Ariel
Blue, Brandon
Ochoa-Bayona, Jose
Smith, Eric
Corallo, Salvatore
Khimani4, Farhad
Faramand, Rawan
Elmariah, Hany
Lazaryan, Aleksandr
Jain, Michael
Liu, Hien
Nishihori, Taiga
Shain, Ken
Baz, Rachid
Alsina, Melissa
Locke, Frederick
Freeman, Ciara
Hansen, Doris
author_sort Mohammed, Turab
collection PubMed
description
format Online
Article
Text
id pubmed-10429647
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-104296472023-08-17 PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA Mohammed, Turab Shahzad, Moazzam Peres, Lauren Khadka, Sushmita Colinleitzinger, Christelle Babu, Abida Doyle, William Puglianini, Omar Castaneda Oswald, Laura De Avila, Gabe Grajales-Cruz, Ariel Blue, Brandon Ochoa-Bayona, Jose Smith, Eric Corallo, Salvatore Khimani4, Farhad Faramand, Rawan Elmariah, Hany Lazaryan, Aleksandr Jain, Michael Liu, Hien Nishihori, Taiga Shain, Ken Baz, Rachid Alsina, Melissa Locke, Frederick Freeman, Ciara Hansen, Doris Hemasphere Publication Only Lippincott Williams & Wilkins 2023-08-08 /pmc/articles/PMC10429647/ http://dx.doi.org/10.1097/01.HS9.0000975160.46377.e2 Text en Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.
spellingShingle Publication Only
Mohammed, Turab
Shahzad, Moazzam
Peres, Lauren
Khadka, Sushmita
Colinleitzinger, Christelle
Babu, Abida
Doyle, William
Puglianini, Omar Castaneda
Oswald, Laura
De Avila, Gabe
Grajales-Cruz, Ariel
Blue, Brandon
Ochoa-Bayona, Jose
Smith, Eric
Corallo, Salvatore
Khimani4, Farhad
Faramand, Rawan
Elmariah, Hany
Lazaryan, Aleksandr
Jain, Michael
Liu, Hien
Nishihori, Taiga
Shain, Ken
Baz, Rachid
Alsina, Melissa
Locke, Frederick
Freeman, Ciara
Hansen, Doris
PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
title PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
title_full PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
title_fullStr PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
title_full_unstemmed PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
title_short PB2092: INCIDENCE AND RISK FACTORS ASSOCIATED WITH BLEEDING FOLLOWING ANTI-B CELL MATURATION ANTIGEN CHIMERIC ANTIGEN RECEPTOR T-CELL THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
title_sort pb2092: incidence and risk factors associated with bleeding following anti-b cell maturation antigen chimeric antigen receptor t-cell therapy in patients with relapsed/refractory multiple myeloma
topic Publication Only
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429647/
http://dx.doi.org/10.1097/01.HS9.0000975160.46377.e2
work_keys_str_mv AT mohammedturab pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT shahzadmoazzam pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT pereslauren pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT khadkasushmita pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT colinleitzingerchristelle pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT babuabida pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT doylewilliam pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT puglianiniomarcastaneda pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT oswaldlaura pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT deavilagabe pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT grajalescruzariel pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT bluebrandon pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT ochoabayonajose pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT smitheric pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT corallosalvatore pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT khimani4farhad pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT faramandrawan pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT elmariahhany pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT lazaryanaleksandr pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT jainmichael pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT liuhien pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT nishihoritaiga pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT shainken pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT bazrachid pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT alsinamelissa pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT lockefrederick pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT freemanciara pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma
AT hansendoris pb2092incidenceandriskfactorsassociatedwithbleedingfollowingantibcellmaturationantigenchimericantigenreceptortcelltherapyinpatientswithrelapsedrefractorymultiplemyeloma

Ejemplares similares